A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 27 150 KRW 2.84% Market Closed
Market Cap: 1.3T KRW
Have any thoughts about
ABL Bio Inc?
Write Note

ABL Bio Inc
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ABL Bio Inc
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Other Equity
â‚©28.4B
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Other Equity
â‚©207.2B
CAGR 3-Years
31%
CAGR 5-Years
36%
CAGR 10-Years
N/A
SK Bioscience Co Ltd
KRX:302440
Other Equity
â‚©10.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Other Equity
-â‚©348.7B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Other Equity
â‚©3.2B
CAGR 3-Years
11%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Other Equity
â‚©7B
CAGR 3-Years
34%
CAGR 5-Years
39%
CAGR 10-Years
N/A
No Stocks Found

ABL Bio Inc
Glance View

Market Cap
1.3T KRW
Industry
Biotechnology

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
8 401.38 KRW
Overvaluation 69%
Intrinsic Value
Price
A

See Also

What is ABL Bio Inc's Other Equity?
Other Equity
28.4B KRW

Based on the financial report for Jun 30, 2024, ABL Bio Inc's Other Equity amounts to 28.4B KRW.

What is ABL Bio Inc's Other Equity growth rate?
Other Equity CAGR 3Y
17%

Over the last year, the Other Equity growth was 25%. The average annual Other Equity growth rates for ABL Bio Inc have been 17% over the past three years .

Back to Top